The investigation determined that a non-reproducible, higher than expected phenytoin (phyt) result was obtained from a single patient sample using vitros chemistry products phyt slides lot 2619-0171-0558 on a vitros 5600 integrated system.The most likely assignable cause is a sample related issue, likely due to improper pre-analytical sample handling protocol.The customer was not able to provide details on the sample appearance at the time of processing, however the sample showed elevated hemolysis and turbidity that increased after the initial run of the sample.Per the vitros phyt instructions for use, hemolyzed samples should not be used.In addition, the customer was not following the sample collection device manufacturer¿s recommendation for sample centrifugation.It is possible that cellular debris, due to poor sample preparation, was present in the affected sample, although this could not be confirmed.Based on historical quality control results, a vitros phyt lot 2619-0171-0558 performance issue is not a likely contributor to the event.Furthermore, continual tracking and trending of complaint data has not identified any signals to suggest there is a systemic quality issue with vitros phyt reagent lot 2619-0171-0558.Additionally, vitros phyt within run precision testing was performed by the customer on the vitros 5600 integrated system.The testing yielded results that were within acceptable guidelines, further indicating a reagent issue is unlikely.The customer did not process a vitros crbm marker precision test as requested to confirm the performance of the analyzer, however, an issue with the vitros 5600 integrated system is unlikely based on historical and current performance.
|
A customer reported a non-reproducible, higher than expected vitros phenytoin (phyt) result from a single patient sample processed using vitros chemistry products phyt slides in combination with a vitros 5600 integrated system.Patient sample result of 21.90 ug/ml vs.An expected result of 17.12 ug/ml.Biased results of the magnitude and direction observed may lead to inappropriate physician action if they were to occur undetected.The higher than expected vitros phyt patient result was reported outside of the laboratory, however, a corrected report was later issued.No treatment was initiated, altered or stopped based upon the initial reported result and ortho has not been made aware of any allegation of patient harm as a result of this event.This report corresponds to ortho clinical diagnostics inc.Complaint numbers (b)(4).
|